Ortho Regenerative Technologies Submits Formal Response to U.S. FDA Clinical Hold

  • All additional CMC-related data and characterization requested submitted
  • Company is confident that additional data submitted makes for a robust and compelling IND package
  • Read full article

Leave a comment

Your email address will not be published. Required fields are marked *